Naltrexone-Bupropion Combination

Phase 3Small molecule

Naltrexone-Bupropion Combination is one of 37 small molecule programs targeting Weight loss. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Weight LossRecruiting

Cardiovascular EventsRecruiting

Weight LossPhase 3

Recruiting

Cardiovascular EventsPhase 3

Recruiting

Competition

Competitive Landscape

35 competitors in Weight Loss

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

13 2

Ozempic

Novo Nordisk

Approved

10 3

Farxiga

AstraZeneca

Approved

4 4

Glucophage

EMD Serono

Approved

8 5

Alli

EEngelhard Arzneimittel GmbH & Co.KG

Approved

7 6

Topamax

WWim Janssens

Approved

3 7

Xifaxan

SSalix

Approved

2 8

Invokana

WWim Janssens

Approved

2 9

Megace

Bristol-Myers Squibb

Phase 3

10 10

Januvia

ZZydus Therapeutics Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Post-ApprovalRecruiting

Weight Loss

NCT05919797

Q2 2028

Post-ApprovalActive, not recruiting

Weight Loss

NCT06854614

Q3 2029

Post-ApprovalRecruiting

Cardiovascular Events

NCT06098079

Clinical

Trials by Indication[1]

Weight loss2 trials

Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)

Active, not recruiting·TThe Cleveland Clinic·Phase 4·NCT06854614·150 enrolled

Weight Loss Study: Genetics and Response to Naltrexone/Bupropion

Recruiting·—·Phase 4·NCT05919797·120 enrolled

Obesity1 trial

Study of the Cardiometabolic Effects of Obesity Pharmacotherapy

Unknown status·NNational and Kapodistrian University of Athens·Phase 4·NCT04575194·40 enrolled

Cardiovascular Events1 trial

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting·CCurrax Pharmaceuticals·Phase 4·NCT06098079·8,600 enrolled

Bariatric Surgery1 trial

Use of Mysimba in Patients With Weight Regain After Bariatric Surgery

Unknown status·ZZuyderland Medisch Centrum·Phase 4·NCT04902625·116 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Naltrexone-Bupropion Combination. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Naltrexone-Bupropion Combination compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Naltrexone-Bupropion Combination. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Currax Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCurrax Pharmaceuticals

Naltrexone-Bupropion Combination

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Q3 2029

Trials by Indication[1]

Weight loss2 trials

Obesity1 trial

Cardiovascular Events1 trial

Bariatric Surgery1 trial

References

Drug Info

Quick Facts

Related News